Identification of S100A9 as biomarker of responsiveness to the methotrexate/etanercept combination in rheumatoid arthritis using a proteomic approach.
One way to optimize the drug prescription in rheumatoid arthritis (RA) is to identify predictive biomarkers of drug responsiveness. Here, we investigated the potential "theranostic" value of proteins of the S100 family by monitoring levels of both S100A8 and S100A9 in blood samples from RA...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2014-01-01
|
| Series: | PLoS ONE |
| Online Access: | http://europepmc.org/articles/PMC4278766?pdf=render |
| _version_ | 1818137829820071936 |
|---|---|
| author | Antoine Obry Thierry Lequerré Julie Hardouin Olivier Boyer Patrice Fardellone Peggy Philippe Xavier Le Loët Pascal Cosette Olivier Vittecoq |
| author_facet | Antoine Obry Thierry Lequerré Julie Hardouin Olivier Boyer Patrice Fardellone Peggy Philippe Xavier Le Loët Pascal Cosette Olivier Vittecoq |
| author_sort | Antoine Obry |
| collection | DOAJ |
| description | One way to optimize the drug prescription in rheumatoid arthritis (RA) is to identify predictive biomarkers of drug responsiveness. Here, we investigated the potential "theranostic" value of proteins of the S100 family by monitoring levels of both S100A8 and S100A9 in blood samples from RA patients.For proteomic analysis, peripheral blood mononuclear cells (PBMC) and serum samples were collected in patients prior to initiation of the methotrexate/etanercept (MTX/ETA) combination. Firstly, relative mass spectrometry (MS) quantification focusing on S100A8 and S100A9 proteins was carried out from PBMCs samples to identify potential biomarkers. The same approach was also performed from serum samples from responder (R) and non responder (NR) patients. Finally, to confirm these results, an absolute quantification of S100A8, S100A9 proteins and calprotectin (heterodimer of S100A8/S100A9) was carried out on the serum samples using ELISA.MS analyses revealed that both S100A8 and S100A9 proteins were significantly accumulated in PBMC from responders. In contrast to PBMC, only the S100A9 protein was significantly overexpressed in the serum of R patients. Absolute quantification by ELISA confirmed this result and pointed out a similar expression level of S100A8 protein and calprotectin in sera from both R and NR groups. Thus, the S100A9 protein revealed to be predictive of MTX/ETA responsiveness, contrarily to parameters of inflammation and auto-antibodies which did not allow significant discrimination.This is the first report of an overexpression of S100A9 protein in both PBMCs and serum of patients with subsequent response to the MTX/ETA combination. This protein thus represents an interesting biomarker candidate of therapeutic response in RA. |
| first_indexed | 2024-12-11T10:02:31Z |
| format | Article |
| id | doaj.art-811f7c297cd4471ea04e7e801c7274ac |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-11T10:02:31Z |
| publishDate | 2014-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-811f7c297cd4471ea04e7e801c7274ac2022-12-22T01:12:05ZengPublic Library of Science (PLoS)PLoS ONE1932-62032014-01-01912e11580010.1371/journal.pone.0115800Identification of S100A9 as biomarker of responsiveness to the methotrexate/etanercept combination in rheumatoid arthritis using a proteomic approach.Antoine ObryThierry LequerréJulie HardouinOlivier BoyerPatrice FardellonePeggy PhilippeXavier Le LoëtPascal CosetteOlivier VittecoqOne way to optimize the drug prescription in rheumatoid arthritis (RA) is to identify predictive biomarkers of drug responsiveness. Here, we investigated the potential "theranostic" value of proteins of the S100 family by monitoring levels of both S100A8 and S100A9 in blood samples from RA patients.For proteomic analysis, peripheral blood mononuclear cells (PBMC) and serum samples were collected in patients prior to initiation of the methotrexate/etanercept (MTX/ETA) combination. Firstly, relative mass spectrometry (MS) quantification focusing on S100A8 and S100A9 proteins was carried out from PBMCs samples to identify potential biomarkers. The same approach was also performed from serum samples from responder (R) and non responder (NR) patients. Finally, to confirm these results, an absolute quantification of S100A8, S100A9 proteins and calprotectin (heterodimer of S100A8/S100A9) was carried out on the serum samples using ELISA.MS analyses revealed that both S100A8 and S100A9 proteins were significantly accumulated in PBMC from responders. In contrast to PBMC, only the S100A9 protein was significantly overexpressed in the serum of R patients. Absolute quantification by ELISA confirmed this result and pointed out a similar expression level of S100A8 protein and calprotectin in sera from both R and NR groups. Thus, the S100A9 protein revealed to be predictive of MTX/ETA responsiveness, contrarily to parameters of inflammation and auto-antibodies which did not allow significant discrimination.This is the first report of an overexpression of S100A9 protein in both PBMCs and serum of patients with subsequent response to the MTX/ETA combination. This protein thus represents an interesting biomarker candidate of therapeutic response in RA.http://europepmc.org/articles/PMC4278766?pdf=render |
| spellingShingle | Antoine Obry Thierry Lequerré Julie Hardouin Olivier Boyer Patrice Fardellone Peggy Philippe Xavier Le Loët Pascal Cosette Olivier Vittecoq Identification of S100A9 as biomarker of responsiveness to the methotrexate/etanercept combination in rheumatoid arthritis using a proteomic approach. PLoS ONE |
| title | Identification of S100A9 as biomarker of responsiveness to the methotrexate/etanercept combination in rheumatoid arthritis using a proteomic approach. |
| title_full | Identification of S100A9 as biomarker of responsiveness to the methotrexate/etanercept combination in rheumatoid arthritis using a proteomic approach. |
| title_fullStr | Identification of S100A9 as biomarker of responsiveness to the methotrexate/etanercept combination in rheumatoid arthritis using a proteomic approach. |
| title_full_unstemmed | Identification of S100A9 as biomarker of responsiveness to the methotrexate/etanercept combination in rheumatoid arthritis using a proteomic approach. |
| title_short | Identification of S100A9 as biomarker of responsiveness to the methotrexate/etanercept combination in rheumatoid arthritis using a proteomic approach. |
| title_sort | identification of s100a9 as biomarker of responsiveness to the methotrexate etanercept combination in rheumatoid arthritis using a proteomic approach |
| url | http://europepmc.org/articles/PMC4278766?pdf=render |
| work_keys_str_mv | AT antoineobry identificationofs100a9asbiomarkerofresponsivenesstothemethotrexateetanerceptcombinationinrheumatoidarthritisusingaproteomicapproach AT thierrylequerre identificationofs100a9asbiomarkerofresponsivenesstothemethotrexateetanerceptcombinationinrheumatoidarthritisusingaproteomicapproach AT juliehardouin identificationofs100a9asbiomarkerofresponsivenesstothemethotrexateetanerceptcombinationinrheumatoidarthritisusingaproteomicapproach AT olivierboyer identificationofs100a9asbiomarkerofresponsivenesstothemethotrexateetanerceptcombinationinrheumatoidarthritisusingaproteomicapproach AT patricefardellone identificationofs100a9asbiomarkerofresponsivenesstothemethotrexateetanerceptcombinationinrheumatoidarthritisusingaproteomicapproach AT peggyphilippe identificationofs100a9asbiomarkerofresponsivenesstothemethotrexateetanerceptcombinationinrheumatoidarthritisusingaproteomicapproach AT xavierleloet identificationofs100a9asbiomarkerofresponsivenesstothemethotrexateetanerceptcombinationinrheumatoidarthritisusingaproteomicapproach AT pascalcosette identificationofs100a9asbiomarkerofresponsivenesstothemethotrexateetanerceptcombinationinrheumatoidarthritisusingaproteomicapproach AT oliviervittecoq identificationofs100a9asbiomarkerofresponsivenesstothemethotrexateetanerceptcombinationinrheumatoidarthritisusingaproteomicapproach |